| |
| |
|
| Insider
Information: |
Booth Bruce |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
4,638,028 |
|
|
Indirect Shares
|
24,465,978 |
|
|
| Direct
Value |
$5,333,732 |
|
|
|
Indirect Value
|
$94,454,667 |
|
|
| Total
Shares |
29,104,006 |
|
|
| Total
Value |
$99,788,400 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 80.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Larimar Therapeutics Inc |
LRMR |
Director, 10% Owner |
2016-01-25 |
4,638,028 |
2014-06-24 |
5,632,730 |
Premium* |
|
|
Viridian Therapeutics Ors Shs |
VRDN |
Director |
|
0 |
2018-02-13 |
4,493,670 |
Premium* |
|
|
Cogent Biosciences, Inc. |
COGT |
Director |
2018-04-03 |
0 |
2018-04-03 |
3,361,535 |
Premium* |
|
|
Dianthus Therapeutics Ord Shs |
DNTH |
Director |
2018-06-25 |
0 |
2020-06-29 |
5,367,125 |
Premium* |
|
|
Kymera Therapeutics, Inc. |
KYMR |
|
|
0 |
2024-06-13 |
802,022 |
Premium* |
|
|
Vigil Neuroscience, Inc. |
VIGL |
Director |
2022-01-11 |
0 |
2022-01-11 |
4,808,896 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
34 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2023-01-11 |
4 |
AS |
$29.96 |
$831,510 |
I/I |
(27,754) |
911,740 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2023-01-12 |
4 |
AS |
$30.29 |
$2,990,229 |
I/I |
(98,720) |
890,148 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-03-11 |
4 |
AS |
$42.77 |
$2,193,148 |
I/I |
(51,184) |
881,266 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-03-12 |
4 |
AS |
$41.94 |
$6,838,813 |
I/I |
(162,918) |
852,995 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-03-13 |
4 |
AS |
$42.19 |
$5,880,415 |
I/I |
(139,255) |
828,830 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-03-14 |
4 |
AS |
$39.73 |
$2,229,927 |
I/I |
(55,779) |
819,151 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-03-15 |
4 |
AS |
$39.31 |
$2,903,336 |
I/I |
(71,764) |
806,697 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-06-12 |
4 |
AS |
$35.35 |
$593,378 |
I/I |
(16,740) |
803,792 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-06-13 |
4 |
AS |
$34.98 |
$356,796 |
I/I |
(10,200) |
802,022 |
0 |
- |
|
34 Records found
|
|
Page 2 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
